The global single nucleotide polymorphisms genotyping market is expected to witness significant growth over the forecast period. Single Nucleotide Polymorphisms (SNP) genotyping is the process of analyzing and screening of genetic variations of SNPs between members of a species. It is an upcoming area of interest for researchers for genomics and life science studies. SNP genotyping has a broad range of applications in a number of industries such as pharmaceuticals, research, agricultural biotechnological, and others which leads to change in dairy and meat yield and crop yields. The use of SNP genotyping is growing rapidly from personalized genetic testing to plant and animal biotechnology. SNP genotyping gives an idea about the human genome characterization and transfer of hereditary diseases. SNP genotyping is of great value for the pharmaceutical and medical fields as it predicts disease association and the response of an individual for a specific medication. Human SNP genotyping has lots of implications in diseases prognosis and treatment, clinical diagnostics, in new drug discovery, and improving the current practice of medicine.
Some of the other driving factors for this market are growing prevalence of fatal diseases such as cancer, diabetes, and others, increasing demand for genetic analysis in animal and plant feedstock, the presence of private and public funding programs in the field of genetics. On the basis of product, single nucleotide polymorphisms genotyping market is segmented into consumables or reagent, instruments, and services. Introduction of technological advancements on the grounds of accuracy, portability, and cost-effectiveness such as growing use of real time and multiplex PCR and massarrays system is expected to drive the market at a rapid pace. On the basis of application, the market is segmented into pharmacogenomics & pharmaceuticals, diagnostic research, breeding & animal livestock, and agricultural biotechnology. On the basis of technology, the SNP genotyping market is classified into taqman allelic discrimination, microarrays & SNP genechips, Sequenom Massarray, MALDI-TOF, applied biosciences SNPlex, SNP pyrosequencing, and other SNP genotyping technologies. Taqman allelic discrimination is the process of identifying one and only one gene or allele with the use of DNA polymerase and ligase enzyme. Sequenom’s massarray system determines SNP by detecting molecular weight of DNA fragments.
Globally single nucleotide polymorphisms (SNP) genotyping market is segmented into four major regions such as Europe, North America, Asia Pacific, and RoW. North America is considered as the most dominant market due to favorable government policies towards proper diagnosis, screening and treatment of fatal diseases, availability of better R&D facilities, and the presence of advanced technologies. Europe and Asia Pacific market are emerging owing to the development of various plans and policies of the government, rising incidences of targeted diseases, improvements in healthcare services, increasing demand for personalized medicines, and rising economic development. Key players in this market area are, Sequenom, Inc., Douglas Scientific LLC, PREMIER Biosoft, Sequenom Inc., Luminex Corp., Life Technologies Corp., Fluidigm, Illumina, Inc., Affymetrix, Inc.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.